Aviso Financial Inc. Sells 6,093 Shares of Boston Scientific Co. (NYSE:BSX)

Aviso Financial Inc. cut its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 26.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,047 shares of the medical equipment provider's stock after selling 6,093 shares during the period. Aviso Financial Inc.'s holdings in Boston Scientific were worth $1,523,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BSX. Raymond James Financial Inc. acquired a new stake in Boston Scientific during the fourth quarter valued at approximately $190,780,000. State Street Corp lifted its position in shares of Boston Scientific by 2.3% in the 3rd quarter. State Street Corp now owns 62,846,328 shares of the medical equipment provider's stock valued at $5,266,522,000 after acquiring an additional 1,389,172 shares in the last quarter. Fisher Funds Management LTD purchased a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $94,710,000. Fisher Asset Management LLC lifted its position in shares of Boston Scientific by 21.6% in the 4th quarter. Fisher Asset Management LLC now owns 5,800,912 shares of the medical equipment provider's stock valued at $518,138,000 after acquiring an additional 1,028,977 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its position in shares of Boston Scientific by 17.5% in the 3rd quarter. Impax Asset Management Group plc now owns 5,470,174 shares of the medical equipment provider's stock valued at $457,138,000 after acquiring an additional 815,403 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the transaction, the executive vice president now directly owns 5,502 shares of the company's stock, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the firm's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the transaction, the executive vice president now directly owns 28,454 shares of the company's stock, valued at $2,966,329.50. The trade was a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 137,302 shares of company stock valued at $14,319,269. Company insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Piper Sandler upped their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Royal Bank of Canada increased their target price on shares of Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Wells Fargo & Company increased their target price on shares of Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a research report on Friday, January 10th. Finally, Morgan Stanley increased their price target on shares of Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Boston Scientific has an average rating of "Moderate Buy" and an average price target of $108.91.

Boston Scientific Stock Performance

NYSE BSX traded up $1.86 during midday trading on Monday, hitting $99.02. The company had a trading volume of 5,703,033 shares, compared to its average volume of 5,721,651. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock has a market cap of $146.14 billion, a price-to-earnings ratio of 79.22, a P/E/G ratio of 2.79 and a beta of 0.77. The firm has a fifty day simple moving average of $101.21 and a two-hundred day simple moving average of $91.97. Boston Scientific Co. has a fifty-two week low of $66.16 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Equities analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.